DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Amatuximab
Amatuximab
Antibody Drug Conjugate Development in Gastrointestinal Cancers: Hopes and Hurdles from Clinical Trials
Preclinical Efficacy of an Antibody–Drug Conjugate Targeting
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
2017 Immuno-Oncology Medicines in Development
The Two Tontti Tudiul Lui Hi Ha Unit
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
Targeting and Efficacy of Novel Mab806-Antibody-Drug Conjugates in Malignant Mesothelioma
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
2016 Medicines in Development for Rare Diseases a LIST of ORPHAN DRUGS in the PIPELINE
(INN) for Biological and Biotechnological Substances
Immunotoxins: Targeted Toxin Delivery for Cancer Therapy
Therapeutically Targeting Glypican-2 Via Single-Domain Antibody-Based
Rare Diseases, When Taken Together, Are Are Together, When Taken Diseases, Rare to According at All
INN Working Document 05.179 Update 2011
Therapeutic Antibody
Stembook 2018.Pdf
Development of More Precise and Efficient Antibodies for Cancer Targeting: Membrane Associated Form Specific Anti- Mesothelin Antibodies and CAR As an Example
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
Top View
2018 Medicines in Development for Cancer
(12) Patent Application Publication (10) Pub. No.: US 2016/0184445 A1 Perroth Et Al
(INN) for Biological and Biotechnological Substances
Safety and Biodistribution of 111In-Amatuximab in Patients With
Orphan Drug Designation List
Study Protocol Morab-009-201 Incorporating Amendment 02
Identification of Pancreatic Cancer-Specific Antigens Using a Novel Quantitative Seroproteomics Approach
2020 Medicines in Development ꟷ Cancer
Orphan Drug Designation List
Amatuximab and Novel Agents Targeting Mesothelin for Solid Tumors
Breast Cancer Cancer Drug Pipeline Information for Patient Advocacy
(2006.01) C07d 413/14
Orphan Drug Designations and Approvals List As of 06‐01‐2015 Governs July 1, 2015 ‐ September 30, 2015
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Anetumab Ravtansine – a Novel Mesothelin-Targeting Antibody-Drug
Personalized Healthcare in Oncology: Past, Present and Future
Oncology Drugs in the Pipeline
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Novel Immunotherapy Clinical Trials in Malignant Pleural Mesothelioma
(INN) for Biological and Biotechnological Substances
Biological Basis for Novel Mesothelioma Therapies
Creating Reports and Visualizations to Support Decision Making with the Bizint Smart Charts Product Family
Early Administration of Amatuximab Suppresses Liver Metastasis Of
Targeting and Efficacy of Novel Mab806
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
(12) United States Patent (10) Patent No.: US 9,364,567 B2 Vitalis Et Al
Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
WO 2018/136663 Al 26 July 2018 (26.07.2018) W !P O PCT
(12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu Et Al